Immunosuppression by human placenta lactogen (HPL) and the pregnancy-specific beta 1-glycoprotein (SP-1). Inhibition of mitogen-induced lymphocyte transformation.
The in vitro effect of human placental lactogen (HPL) and the gravidity-specific beta1-Glycoprotein (SP-1) on the lymphocyte transformation was investigated in 20 healthy women. It was shown that simultaneous incubation of the lymphocytes with HPL or SP-1 together with PHA has no influence on the incorporation rate of H3-Thymidine. When the fetal calf serum (FCS) in the lymphocyte cultures was substituted by a 3% human albumin-solution, there was a reduction of the incorporation rate of the radioactive nucleic acid precursors to 20%, as compared to the controls with FCS. After addition of HPL and SP-1 to the cultures there was a further dosis dependent decrease of the incorporation rate. When lymphocytes were preincubated with the proteins for 24 h, there was a marked reduction of the blastogenesis after additon of PHA, HPL and SP-1 under these conditions had a immunosuppressive effect on the lymphocyte transformation.
D000818:Animals; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents; D037102:Lectins; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000378:metabolism; D010928:Placental Lactogen / Q000494:pharmacology*; D011247:Pregnancy; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D006023:Glycoproteins; D007166:Immunosuppressive Agents; D037102:Lectins; D014316:Tritium; D010928:Placental Lactogen; D013936:Thymidine